

Press Release: Winner of ICI Innovation Award Announced

EMBARGOED UNTIL 1030am Tuesday 4th December Tel Aviv, Israel... Today in Tel Aviv, the winner of the ICI Innovation Awards Best Business Start-Up Award for 2012 was announced in front of an audience of 1200 international cardiologists.

The winner was a British company, Sky Medical Ltd, for their device geko™, a non-invasive method to prevent deep vein thrombosis.



The one size fits all, geko™ device uses patented technology to stimulate the nerve at the back of the knee and stimulate contraction of the calf, shin and foot muscles. This improves blood circulation and oxygen levels almost equivalent of walking but when the patient is not mobile, for example after surgery or during a long haul airplane journey.

The company believe that the technology can replace the need for cumbersome foot pumps or other mechanical devices that are currently in use, but unlike the existing devices allow the patient to get up from bed and mobilise early.

"In the UK, there are more deaths per year from blood clots than from breast cancer, road traffic accidents and AIDS combined, and this inspired us to find a better solution than already existed ." said Bernard Ross, CEO of Sky Medical Technology Limited.

"We are honoured to have won this prestigious Award, judged by some of the world's foremost experts in the field" he continued. *"This will help increase our visibility to the clinical world and speed up adoption of this important technology to improve patient care"*.

Chairman of the Judging Panel, Professor Martin Rothman stated, *"The Judges were enthused by the wealth of innovation and entrepreneurship displayed by the shortlisted candidates. The winner was selected because of its simplicity, clear potential to have clinical impact and business opportunity"*

"Innovation is the life blood for any organisation and over the coming years of economic uncertainty, there has never been a more pressing demand for healthcare innovation." Said Professor Chaim Lotan, Director of the ICI Meeting.

"The ICI Innovation Awards is the world's largest and prestigious award for cardiovascular start-ups. To have seen applications for our competition from 22 countries around the world is very exciting". Said Professor Rafi Beyar, Co-Director of the ICI Meeting.

ENDS.

VASCULAR MIND



Title: Twister® - Endovascular Embolisation and Occlusion Concept

Pelvic Congestion Syndrome and related pain is very common in women, significantly affecting their quality of life. Embolisation of incompetent veins is a promising treatment but only if migration of embolic material and correlated pulmonary embolism risk can be avoided. The Twister® device is designed to produce endovascular controlled occlusion over a working catheter allowing safe embolisation. At least 30% of women suffering from pelvic congestion could benefit of the Twister® technique. Animal feasibility study are now complete and the concept moves to first in man studies.

What the company is seeking: Investment, and an increased awareness of a common problem and our novel solution.

Contacts

Name: Claude Mialhe
Tel: +(33) 6 09 77 14 52

Email: claudio.mialhe@wanadoo.fr
Location: France

SMART-PRAXIS



Title of Innovation: "Remote-K-Viewer" - Remote Programming of Cardiac Devices

The "remote-K-viewer" is a hardware and software system that allows remote, real-time, visualization and guided reprogramming of any implantable cardiac device allowing prompt care to patients, in a more cost effective way. The standard way of managing a cardiac device is with a *programmer* (dedicated company computer) that directly interacts with the patient. The programmer requires the physical presence of company representative or a specialist at the bedside, a costly resource. The "remote-K-viewer" permits a remote "expert" operator using devices such as the iPad to guide a bedside operator "non-expert" user such as a nurse in real-time.

Dr Martin Kloosterman, founder of the technology said, "If we can remotely control a robot in Mars, we can certainly do so with pacemaker or defibrillator in Earth, but we haven't until now!"

What the company is seeking: Assistance, contacts and partnering opportunities.

Contacts

Name: Dr. Martin Kloosterman
Tel: +(1) 954-261-3262 (US#)

Email: Martin.kloosterman@yahoo.com
Location: Florida, USA

SENSIBLE MEDICAL



Title of Innovation: Sensible Medical Innovations

Sensible Medical Innovations has developed a proprietary medical radar monitoring and imaging technology (ReDS™). The company's first application focuses on Congestive Heart Failure (CHF), the leading cause of hospitalizations worldwide for elderly adults. The small device, worn on top of the clothes, monitors lung fluid in a non-invasive manner, at home, or in the hospital and provides early detection of heart failure exacerbation. Sensible aims to demonstrate a 50% reduction in hospital readmissions of heart failure patients.

What the company is seeking: Recognition and contacts

Contacts

Name: Mr Amir Ronen
Tel: +972 986 54402

Email: yael.k@sensible-medical.com
Location: Israel

www.sensible-medical.com

MEDISPEC



Title of Innovation:

Extracorporeal Shockwave Myocardial Revascularization Therapy

Cardiospec is a medical device for treating end-stage coronary artery disease using low intensity shock waves to stimulate blood vessels formation in the heart muscle (angiogenesis). The Cardiospec treatment is non-invasive and has been used in several clinical studies to date.

What the company is seeking: Assistance, recognition and contacts

Contacts

Name: Revital Shalem
Tel: +972 363 22088

Email: vital@medispec-int.com
Location: Israel

LADY DAVIS CARMEL MEDICAL CENTER

Title: EmboPro Proximal Embolic Protection Device and Thrombus Aspiration Catheter

EmboPRO is a device designed for prevention of downstream embolization of clot and plaque, causing blockage of smaller vessels, during coronary interventions such as stenting. EmboPRO offers a combination of improved thrombus aspiration and user-friendly embolic protection in a single device constituting a significant advance over current devices in the market. EmboPRO has been tested in animals and has the support of leading interventional cardiologists. Clinical testing is planned for 2013. CardioFlow, which employs three device professionals, expects to benefit from industry exposure from its participation in the ICI awards.

What the company is seeking: Recognition and contacts.

Contacts

Name: Aaron Feldman, CEO
Tel: +972 506 265830

Email: Aaron@cardioflowmed.com
Location: Israel

www.cardioflowmed.com

HDH MEDICAL LIMITED



Title of Innovation:

B.Y.Fix Suture-Less Anastomotic Device

HDH Medical has developed and commercialized in Europe the BYFix innovative medical device for creating suture-less anastomosis (connection) of blood vessels. BYFix is used to treat potentially life threatening conditions such as arterial occlusions, traumas and aneurysms safely, simply and cost effectively, as confirmed by leading Israeli and German vascular surgeons who have treated more than 50 patients to date.

What the company is seeking: Contacts and investors

Contacts

Name: Irina Kavounovski
Tel: +972 646 2215

Email: irina@hdhmedical.com
Location: Israel

www.hdhmedical.com

VIRON THERAPEUTICS



Title of Innovation:

VT-111, a Revolutionary Treatment for Coronary Intervention

Viron Therapeutics is a biopharmaceutical company focused on the discovery and development of novel therapeutics. Viron's approach to drug discovery has produced some of the most potent anti-inflammatory molecules ever developed. Viron's lead compound, VT-111a, is a recombinant protein able to inhibit monocyte migration and inflammatory processes. In a Phase 2a clinical trial, VT-111 was shown to significantly impact biomarkers of cardiac tissue injury, and the company hope will improve the clinical outcomes for patients with cardiac disease.

What the company is seeking: Contacts and further funding

Contacts

Name: Elaine King

Email: eking@vironinc.com

Tel: +1 519 858 5156

Location: Ontario, Canada

www.vironinc.com

About the ICI Innovation Best Start-Up Innovation Award

The ICI Innovation Award offers cardiovascular Start-Up's the opportunity to obtain critical peer review and feedback from a world class panel of clinical and commercial experts. Entrants are invited to pitch their idea face to face to the Who's Who panel of experts who then quiz them on the clinical and commercial opportunity. The panel of Judges determine the winner based on three principal criteria: The impact on novelty; impact on patient care; and the business potential.

Winning an ICI Innovation Award offers unparalleled clinical and commercial validation. The winner is offered assistance, guidance and contacts to drive the idea towards benefitting patients. Winners also are offered the opportunity to present their innovation to thousands of doctors both at the ICI Meeting as well as at Europe's largest cardiovascular meeting, EuroPCR in May 2013.

The ICI Innovation Awards are run in association with the "Innovations in Cardiovascular Interventions" (ICI) Meeting which takes place in December in Tel Aviv in Israel (see www.icimeeting.com) The competition is in its second year, and each year more than 70 applications from 22 countries around the world enter and are whittled down to a shortlist of just 10 who are invited to present. The Awards are supported by an unrestricted educational grant from Medtronic Inc.

Entries for the 2013 ICI Innovation Awards will open in Spring 2013.

For further details on the Award Judges please see <http://ici.medicalfutures.co.uk>

Contact: Martine Morris Email: martine@medicalfutures.co.uk

Telephone: +44(0)7939 801 100